TransCode Therapeutics Ownership 2024 | Who Owns TransCode Therapeutics Now?
Institutional Ownership
0.09%
Insider Ownership
0.05%
Retail Ownership
99.86%
Institutional Holders
11.00
TransCode Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
WELLS FARGO & COMPANY/MN | - | - | - | -51 | -100.00% | - | Jun 30, 2023 |
STATE STREET CORP | - | - | - | -21,019 | -100.00% | - | Jun 30, 2023 |
GOLDMAN SACHS GROUP INC | - | - | - | -13,122 | -100.00% | - | Jun 30, 2023 |
SHEETS SMITH WEALTH MANAGEMENT | - | - | - | -60,000 | -100.00% | - | Jun 30, 2023 |
TWO SIGMA INVESTMENTS, LP | - | - | - | -19,407 | -100.00% | - | Jun 30, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -75,683 | -100.00% | - | Jun 30, 2023 |
BLACKROCK INC. | - | - | - | -1,385 | -100.00% | - | Jun 30, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -6,351 | -100.00% | - | Jun 30, 2023 |
WARBERG ASSET MANAGEMENT LLC | - | - | - | -20,000 | -100.00% | - | Jun 30, 2023 |
SHAY CAPITAL LLC | - | - | - | -15,060 | -100.00% | - | Jun 30, 2023 |
ONE68 GLOBAL CAPITAL, LLC | - | - | - | -30,120 | -100.00% | - | Jun 30, 2023 |
TransCode Therapeutics's largest institutional shareholder is WELLS FARGO & COMPANY/MN, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.
Institutional Shareholders by % of Total Assets
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
WELLS FARGO & COMPANY/MN | - | - | - | -51 | -100.00% | - | Jun 30, 2023 |
STATE STREET CORP | - | - | - | -21,019 | -100.00% | - | Jun 30, 2023 |
GOLDMAN SACHS GROUP INC | - | - | - | -13,122 | -100.00% | - | Jun 30, 2023 |
SHEETS SMITH WEALTH MANAGEMENT | - | - | - | -60,000 | -100.00% | - | Jun 30, 2023 |
TWO SIGMA INVESTMENTS, LP | - | - | - | -19,407 | -100.00% | - | Jun 30, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -75,683 | -100.00% | - | Jun 30, 2023 |
BLACKROCK INC. | - | - | - | -1,385 | -100.00% | - | Jun 30, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -6,351 | -100.00% | - | Jun 30, 2023 |
WARBERG ASSET MANAGEMENT LLC | - | - | - | -20,000 | -100.00% | - | Jun 30, 2023 |
SHAY CAPITAL LLC | - | - | - | -15,060 | -100.00% | - | Jun 30, 2023 |
ONE68 GLOBAL CAPITAL, LLC | - | - | - | -30,120 | -100.00% | - | Jun 30, 2023 |
The largest TransCode Therapeutics shareholder by % of total assets is WELLS FARGO & COMPANY/MN. The company owns 0.00 shares of TransCode Therapeutics (RNAZ), representing 0.00% of its total assets.
Institutional Buyers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
WELLS FARGO & COMPANY/MN | - | - | - | -51 | -100.00% | - | Jun 30, 2023 |
BLACKROCK INC. | - | - | - | -1,385 | -100.00% | - | Jun 30, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -6,351 | -100.00% | - | Jun 30, 2023 |
GOLDMAN SACHS GROUP INC | - | - | - | -13,122 | -100.00% | - | Jun 30, 2023 |
SHAY CAPITAL LLC | - | - | - | -15,060 | -100.00% | - | Jun 30, 2023 |
TWO SIGMA INVESTMENTS, LP | - | - | - | -19,407 | -100.00% | - | Jun 30, 2023 |
WARBERG ASSET MANAGEMENT LLC | - | - | - | -20,000 | -100.00% | - | Jun 30, 2023 |
STATE STREET CORP | - | - | - | -21,019 | -100.00% | - | Jun 30, 2023 |
ONE68 GLOBAL CAPITAL, LLC | - | - | - | -30,120 | -100.00% | - | Jun 30, 2023 |
SHEETS SMITH WEALTH MANAGEMENT | - | - | - | -60,000 | -100.00% | - | Jun 30, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -75,683 | -100.00% | - | Jun 30, 2023 |
As of Jun 30 2023, TransCode Therapeutics's largest institutional buyer is WELLS FARGO & COMPANY/MN. The company purchased -51.00 stocks of RNAZ, valued at -.
Institutional Sellers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -75,683 | -100.00% | - | Jun 30, 2023 |
SHEETS SMITH WEALTH MANAGEMENT | - | - | - | -60,000 | -100.00% | - | Jun 30, 2023 |
ONE68 GLOBAL CAPITAL, LLC | - | - | - | -30,120 | -100.00% | - | Jun 30, 2023 |
STATE STREET CORP | - | - | - | -21,019 | -100.00% | - | Jun 30, 2023 |
WARBERG ASSET MANAGEMENT LLC | - | - | - | -20,000 | -100.00% | - | Jun 30, 2023 |
TWO SIGMA INVESTMENTS, LP | - | - | - | -19,407 | -100.00% | - | Jun 30, 2023 |
SHAY CAPITAL LLC | - | - | - | -15,060 | -100.00% | - | Jun 30, 2023 |
GOLDMAN SACHS GROUP INC | - | - | - | -13,122 | -100.00% | - | Jun 30, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -6,351 | -100.00% | - | Jun 30, 2023 |
BLACKROCK INC. | - | - | - | -1,385 | -100.00% | - | Jun 30, 2023 |
WELLS FARGO & COMPANY/MN | - | - | - | -51 | -100.00% | - | Jun 30, 2023 |
As of Jun 30 2023, TransCode Therapeutics's biggest institutional seller is GEODE CAPITAL MANAGEMENT, LLC. The company sold -75.68K shares of RNAZ, valued at -.
Institutional New positions
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|
Institutional Sold Out
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -75,683 | -100.00% | - | Jun 30, 2023 |
SHEETS SMITH WEALTH MANAGEMENT | - | - | - | -60,000 | -100.00% | - | Jun 30, 2023 |
ONE68 GLOBAL CAPITAL, LLC | - | - | - | -30,120 | -100.00% | - | Jun 30, 2023 |
STATE STREET CORP | - | - | - | -21,019 | -100.00% | - | Jun 30, 2023 |
WARBERG ASSET MANAGEMENT LLC | - | - | - | -20,000 | -100.00% | - | Jun 30, 2023 |
TWO SIGMA INVESTMENTS, LP | - | - | - | -19,407 | -100.00% | - | Jun 30, 2023 |
SHAY CAPITAL LLC | - | - | - | -15,060 | -100.00% | - | Jun 30, 2023 |
GOLDMAN SACHS GROUP INC | - | - | - | -13,122 | -100.00% | - | Jun 30, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -6,351 | -100.00% | - | Jun 30, 2023 |
BLACKROCK INC. | - | - | - | -1,385 | -100.00% | - | Jun 30, 2023 |
WELLS FARGO & COMPANY/MN | - | - | - | -51 | -100.00% | - | Jun 30, 2023 |
TransCode Therapeutics's largest sold out institutional shareholder by shares sold is GEODE CAPITAL MANAGEMENT, LLC, sold -75.68K shares, valued at -, as of undefined.
TransCode Therapeutics Mutual Fund Holders
Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
---|---|---|---|---|---|
VANGUARD INDEX FUNDS | 0.00% | 200,117 | - | - | Mar 31, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 74,374 | - | - | Feb 29, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 52,326 | - | - | Feb 29, 2024 |
USAA MUTUAL FUNDS TRUST | 0.00% | 1,131 | - | - | Jan 31, 2024 |
EQ ADVISORS TRUST | 0.00% | 1,385 | - | - | Mar 31, 2024 |
iSHARES TRUST | 0.00% | 14,293 | - | - | Mar 31, 2024 |
TransCode Therapeutics's largest mutual fund holder by % of total assets is "VANGUARD INDEX FUNDS", owning 200.12K shares, compromising 0.00% of its total assets.
TransCode Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
Date | Holdings | Change % |
---|---|---|
31 Mar, 23 | 11 | -38.89% |
31 Dec, 22 | 18 | 63.64% |
30 Sep, 22 | 11 | -8.33% |
30 Jun, 22 | 12 | - |
31 Mar, 22 | 12 | -14.29% |
31 Dec, 21 | 14 | -12.50% |
30 Sep, 21 | 16 | - |
As of 31 Mar 23, 11 institutions are holding TransCode Therapeutics's shares, representing a decrease of -38.89% compared to the previous quarter.
Shares Outstanding Trend
Date | Shares Outstanding | Change % |
---|---|---|
31 Mar, 23 | 262,198 | -24.05% |
31 Dec, 22 | 345,210 | -83.28% |
30 Sep, 22 | 2,064,102 | -0.99% |
30 Jun, 22 | 2,084,804 | 91.33% |
31 Mar, 22 | 1,089,616 | -53.71% |
31 Dec, 21 | 2,354,078 | -3.35% |
30 Sep, 21 | 2,435,791 | - |
TransCode Therapeutics (RNAZ) has 262.20K shares outstanding as of 31 Mar 23, down -24.05% compared to the previous quarter.
Institutional Ownership Trend
Date | Ownership % | Change % |
---|---|---|
31 Mar, 23 | 0.09% | 633.44% |
31 Dec, 22 | 0.12% | 18.95% |
30 Sep, 22 | 0.80% | 123.25% |
30 Jun, 22 | 0.80% | 455.76% |
31 Mar, 22 | 0.42% | 40.26% |
31 Dec, 21 | 1.02% | 91.47% |
30 Sep, 21 | 1.06% | - |
As of 31 Mar 23, TransCode Therapeutics is held by 0.09% institutional shareholders, representing a 633.44% growth compared to 31 Dec 22.
Institutional Increased Positions Trend
Date | Increased Positions | Change % |
---|---|---|
31 Mar, 23 | 4 | -73.33% |
31 Dec, 22 | 15 | - |
30 Sep, 22 | - | -100.00% |
30 Jun, 22 | 4 | - |
31 Mar, 22 | 4 | -50.00% |
31 Dec, 21 | 8 | -50.00% |
30 Sep, 21 | 16 | - |
4 institutional shareholders have increased their position in RNAZ stock as of 31 Mar 23 compared to 15 in the previous quarter (a -73.33% decrease).
Institutional Reduced Positions Trend
Date | Reduced Positions | Change % |
---|---|---|
31 Mar, 23 | 3 | - |
31 Dec, 22 | - | -100.00% |
30 Sep, 22 | 3 | 50.00% |
30 Jun, 22 | 2 | -50.00% |
31 Mar, 22 | 4 | 300.00% |
31 Dec, 21 | 1 | - |
30 Sep, 21 | - | - |
3 institutional shareholders have reduced their position in RNAZ stock as of 31 Mar 23 compared to - in the previous quarter (a 0.00% increase).
All Institutional Ownership Trend Data
Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar, 23 | 11 | -38.89% | 262,198 | -24.05% | 0.09% | 633.44% | 4 | -73.33% | 3 | - |
31 Dec, 22 | 18 | 63.64% | 345,210 | -83.28% | 0.12% | 18.95% | 15 | - | - | -100.00% |
30 Sep, 22 | 11 | -8.33% | 2,064,102 | -0.99% | 0.80% | 123.25% | - | -100.00% | 3 | 50.00% |
30 Jun, 22 | 12 | - | 2,084,804 | 91.33% | 0.80% | 455.76% | 4 | - | 2 | -50.00% |
31 Mar, 22 | 12 | -14.29% | 1,089,616 | -53.71% | 0.42% | 40.26% | 4 | -50.00% | 4 | 300.00% |
31 Dec, 21 | 14 | -12.50% | 2,354,078 | -3.35% | 1.02% | 91.47% | 8 | -50.00% | 1 | - |
30 Sep, 21 | 16 | - | 2,435,791 | - | 1.06% | - | 16 | - | - | - |
TransCode Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
---|
All Insider Owners Trades
The last insider buy of RNAZ was made by Fitzgerald Thomas A on Oct 02 2023, buying 49,350 shares at $0.51 per share (worth $25.17K).
TransCode Therapeutics Insider Ownership Trends
All Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q2 2023 | 12 | - | - |
Q4 2022 | 3 | - | - |
Q3 2022 | 1 | - | - |
Q2 2022 | 5 | - | - |
Q1 2022 | 4 | - | - |
Q3 2021 | - | 8 | - |
12 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by TransCode Therapeutics's insiders, as of Q2 2023.
Open Market Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q2 2023 | 4 | - | - |
Q4 2022 | - | - | - |
Q3 2022 | 1 | - | - |
Q2 2022 | 2 | - | - |
Q1 2022 | - | - | - |
Q3 2021 | - | - | - |
As of Q2 2023, Insider owners conducted 4 open market buy trades and 0 open market sell trades of TransCode Therapeutics's stocks.
TransCode Therapeutics Peer Ownership
Ticker | Company |
---|---|
ZVSA | ZyVersa Therapeutics, Inc. |
CNSP | CNS Pharmaceuticals, Inc. |
ONCR | Oncorus, Inc. |
XBIO | Xenetic Biosciences, Inc. |
NEXI | NexImmune, Inc. |
PHIO | Phio Pharmaceuticals Corp. |
REVB | Revelation Biosciences, Inc. |
LABP | Landos Biopharma, Inc. |
EFTR | eFFECTOR Therapeutics, Inc. |
KOD | Kodiak Sciences Inc. |
EYEN | Eyenovia, Inc. |
IMMX | Immix Biopharma, Inc. |
SONN | Sonnet BioTherapeutics Holdings, Inc. |
CGTX | Cognition Therapeutics, Inc. |
ZURA | Zura Bio Limited |
RNAZ Ownership FAQ
Who Owns TransCode Therapeutics?
TransCode Therapeutics is owned by institutional shareholders (0.09%), insiders (0.05%), and public (99.86%). The largest institutional shareholder of TransCode Therapeutics is WELLS FARGO & COMPANY/MN (0% of total shares) and the top mutual fund owner is VANGUARD INDEX FUNDS (0.00% of total shares).
Who are the major institutional shareholders of TransCode Therapeutics?
TransCode Therapeutics's major institutional shareholders are WELLS FARGO & COMPANY/MN, STATE STREET CORP, GOLDMAN SACHS GROUP INC, SHEETS SMITH WEALTH MANAGEMENT, and TWO SIGMA INVESTMENTS, LP. The top five shareholders own together 0% of the company's share outstanding.
How many TransCode Therapeutics shareholders are there?
As of Mar 2023, there are 11 institutional shareholders of TransCode Therapeutics.
What percentage of TransCode Therapeutics is owned by WELLS FARGO & COMPANY/MN?
WELLS FARGO & COMPANY/MN owns 0 shares of TransCode Therapeutics, representing 0% of the company's total shares outstanding, valued at $0 (as of Jun 2023).
What percentage of TransCode Therapeutics is owned by STATE STREET CORP?
As of Jun 2023, STATE STREET CORP holds 0 shares of TransCode Therapeutics (RNAZ), compromising 0% of the company, valued at $0.
What percentage of TransCode Therapeutics is owned by GOLDMAN SACHS GROUP INC?
GOLDMAN SACHS GROUP INC is the third largest holder of TransCode Therapeutics. The company owns 0 of the company's shares outstanding (worth $0).